天辰生物，专注于过敏性疾病和自身免疫系统疾病的药物开发，服务于患者和社会。
天辰生物的联合创始人，孙乃超博士，Bill， Nai-chau，也是Tanox的联合创始人。他也是第一种获批的抗IgE抗体Omalizumab（Xolair®）的共同发明者。
目标是为患者带来更实惠、高质量的生物药物。
我们的领先管线是下一代抗IgE抗体（LP-003），目前正处于临床III期阶段，计划于2026年第三季度或之前提交BLA。第二个领先管线是双功能补体抑制剂（LP-005），目前处于临床II期阶段。
Dr Sun, Bill Nai-chau co-founded Longbio in 2018. He is also a member of the Board at present.
Dr. Sun boasts a distinguished career as a serial entrepreneur, marked by numerous successes. Notably, he co-founded Tanox Inc. in 1986 and led its R&D department. Tanox, a biotech company based in Houston, US, went public on Nasdaq in 2000. In a significant milestone, the company was acquired by Genentech in 2006 for a staggering sum of 919 million USD. During his tenure at Tanox, Dr. Sun served as the main inventor behind the groundbreaking first-generation anti-IgE antibody, Omalizumab (marketed as Xolair®), which emerged as a blockbuster in asthma and allergic diseases. Since its listing over two decades ago, Omalizumab has amassed cumulative sales revenue exceeding 30 billion USD, with annual revenues still surpassing 3.5 billion USD. Prior to his involvement with Longbio, Dr. Sun held the position of Founder and President at Xuhua, a drug discovery company in China, starting from 2001. Under his leadership, Xuhua collaborated on several innovative drug projects with listed companies in China, including the successful approval of Benegrastim (marketed as Ryzneuta®) by the US FDA and China NMPA in 2023. Dr. Sun's early career included research roles at Oak Ridge National Laboratory and the National Cancer Institute. He earned his Ph.D. from Iowa State University.
Dr. Liu, our co-founder, has over 15 years of experience in research and
development and commercialization of biopharmaceutical drugs. Dr. Liu played a pivotal role
in both domestic and international programs of development of several innovative drugs.
Notably, Dr. Liu was deeply involved in the development of a long-acting G-CSF (marketed
as Ryzneuta®), which successfully completed phase III clinical trials globally and received
market approval from the Food and Drug Administration in the United States and the NMPA.
